Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells

Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells

Background Whereas chimeric antigen receptor gene modified T (CAR-T) cell therapy has been clinically applied to malignant lymphomas and multiple myeloma, CAR-T cell therapy for solid tumors has so far not reached clinical application. Epithelial V-like antigen 1 (Eva1), transcribed from myelin prot...

Full description

Saved in:
Bibliographic Details
Main Authors: Masaki Sunagawa, Yuki Takeuchi, Tomoki Ebata, Seitaro Terakura, Yutaka Hatanaka, Hitoshi Kiyoi, Masahide Osaki, Shiho Hirano, Takuma Iwasa, Kanako C Hatanaka, Toshio Kokuryo, Yoshitaka Adachi, Ryo Hanajiri, Chie Sakanaka, Makoto Murata
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e009825.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/5/e009825.full

Similar Items